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Mendelian adult-onset leukodystrophies are a spectrum of rare inherited progressive neurodegenerative
disorders affecting the white matter of the central nervous system. Among these, cerebral autosomal
dominant and recessive arteriopathy with subcortical infarcts and leukoencephalopathy, cerebroretinal
vasculopathy, metachromatic leukodystrophy, hereditary diffuse leukoencephalopathy with spheroids,
and vanishing white matter disease present with rapidly progressive dementia as dominant feature and
are caused by mutations in NOTCH3, HTRA1, TREX1, ARSA, CSF1R, EIF2B1, EIF2B2, EIF2B3, EIF2B4, and
EIF2B5, respectively. Given the rare incidence of these disorders and the lack of unequivocally diagnostic
features, leukodystrophies are frequently misdiagnosed with common sporadic dementing diseases such
as Alzheimer’s disease (AD), raising the question of whether these overlapping phenotypes may be
explained by shared genetic risk factors. To investigate this intriguing hypothesis, we have combined
gene expression analysis (1) in 6 different AD mouse strains (APPPS1, HOTASTPM, HETASTPM, TPM,
TAS10, and TAU) at 5 different developmental stages (embryo [E15], 2, 4, 8, and 18 months), (2) in APPPS1
primary cortical neurons under stress conditions (oxygen-glucose deprivation) and single-variantebased
and single-geneebased (c-alpha test and sequence kernel association test (SKAT)) genetic screening in a
cohort composed of 332 Caucasian late-onset AD patients and 676 Caucasian elderly controls. Csf1r was
significantly overexpressed (log2FC > 1, adj. p-value < 0.05) in the cortex and hippocampus of aged
HOTASTPM mice with extensive Ab dense-core plaque pathology. We identified 3 likely pathogenic
mutations in CSF1R TK domain (p.L868R, p.Q691H, and p.H703Y) in our discovery and validation cohort,
composed of 465 AD and mild cognitive impairment (MCI) Caucasian patients from the United Kingdom.imental Neurology, Charite’,
149; fax: 030 450 560 915.
E-mail address: celeste.sassi@charite.de (C. Sassi).
Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C. Sassi et al. / Neurobiology of Aging 66 (2018) 179.e17e179.e29179.e18Moreover, NOTCH3 was a significant hit in the c-alpha test (adj p-value ¼ 0.01). Adult-onset Mendelian
leukodystrophy genes are not common factors implicated in AD. Nevertheless, our study suggests a
potential pathogenic link between NOTCH3, CSF1R, and sporadic late-onset AD, which warrants further
investigation.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mendelian adult-onset leukodystrophies are a spectrum of rare
chronic progressive disorders affecting the white matter of the
central nervous system. Although a growing body of literature is
reporting newly discovered forms, the most characterized adult-
onset leukodystrophies are cerebral autosomal dominant and
recessive arteriopathy with subcortical infarcts and leukoencephal-
opathy (CADASIL and CARASIL), cerebroretinal vasculopathy (CRV),
metachromatic leukodystrophy (MLD), hereditary diffuse leu-
koencephalopathy with spheroids (HDLS) and vanishing white
matter disease (VWM), caused by mutations in NOTCH3, HTRA1,
TREX1, ARSA, CSF1R, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, respec-
tively (Joutel et al., 1996), (Hara et al., 2009), (Richards et al., 2007),
(Fluharty et al., 1991), (Rademakers et al., 2011), (Scali et al., 2006).
Given the rare incidence of these disorders (5/100,000 to only few
cases reported), the lack of peculiar and distinctive (1) clinical fea-
tures, generally represented by rapidly progressive dementia,
behavioral changes, pyramidal and extrapyramidal signs and, less
commonly, ischemic strokes and epileptic seizures; (2) magnetic
resonance imaging (MRI) lesion patterns, normally characterized by
T2-weighted periventricular and subcortical, patchy and later
confluent white matter hyperintensities with prominent frontal
involvement; and (3) neuropathological features, frequently a com-
bination of diverse neurodegenerative hallmarks, these rare Men-
delian disorders are most frequently underrecognized and
misdiagnosedwith common sporadic dementias such as Alzheimer’s
disease (AD). On the other hand, motor features like ataxia and
spasticity may appear in the course of AD progression, particularly in
the cases caused by or associated to PSEN1 mutations (Rossor et al.,
2010) and AD patients may display MRI patterns and neuropatho-
logical features typical of adult-onset leukodystrophies (Smith et al.,
2000;Marnane et al., 2016; Barber et al.,1999; Guerreiro et al., 2013),
suggesting a potential common pathogenic ground.
In the past 10 years, next-generation sequencing (NGS) paved the
way for groundbreaking discoveries in AD, showing that Mendelian
rare disorders offer a unique window into the sporadic complex
traits and, particularly, that rare alleles in TREM2, TYROBP, and
NOTCH3, causative for adult-onset leukodystrophies, significantly
influence the susceptibility for AD (Guerreiro et al., 2012; Guerreiro
et al., 2013; Ma et al., 2015). Moreover, the sequencing of different
mouse strains showed extensive similarities between mouse and
human genome and validated the importance of using mouse
models to illuminate the genetics of human diseases (Cheng et al.,
2014; Yue et al., 2014). Nevertheless, NGS still presents 2 main
challenges: (1) the huge amount of data generated is difficult tomine
and (2) the investigation of rare coding variants requires several
thousands of samples. Consequently, the need for experimental
methods that accurately identify critical genes and strategies to
empower association studies became priorities. Therefore, we have
applied a combination of cortical and hippocampal gene expression
analysis in 6 diverse AD mouse strains (APPPS1, HOTASTPM,
HETASTPM, TPM, TAS10, and TAU) at 5 different developmental
stages (embryo [E15], 2, 4, 8 and 18 months) to comprehensively
study leukodystrophy gene expression pattern in relation to the
progression of AD neuropathology and under stress conditions such
as oxygen-glucose deprivation (OGD), which represents an in vitromodel of ischemic stroke, a common feature in several adult-onset
leukodystrophies and frequent comorbidity in AD. We then used
exome and genome sequencing data in a cohort composed of 332
Caucasian late-onset AD (LOAD) patients and 676 Caucasian elderly
controls to investigate rare coding variability in these main adult-
onset Mendelian leukodystrophy genes. Among the studied genes,
Csf1r was the only gene significantly overexpressed (log2FC>1, p-
value < 0.05) in AD mouse models and its expression tightly corre-
lated with the severity of dense-core plaque deposition. Moreover,
we identified a total of 3 rare variants in CSF1R tyrosine kinase (TK)
domain and TK flanking regions (p.L868R and p.D565N, p.G957R,
respectively) present only in cases and very likely pathogenic. We
then screened CSF1R in an independent cohort composed of 465
mild cognitive impairment (MCI) and AD cases, identifying 2 addi-
tional mutations in CSF1R TK domain (p.Q691H and p.H703Y).
Finally, NOTCH3 was a significant hit in the gene-based analysis (adj
p-value¼ 0.01), suggesting a potential role as a disease modifier. We
conclude that rare coding variability in adult-onset Mendelian leu-
kodystrophy genes is not a common risk factor for AD. However,
CSF1R coding variants clustering in the TK domain and NOTCH3may
influence AD susceptibility.
2. Materials and methods
2.1. Adult-onset leukodystrophy gene selection
The selected genes are all Mendelian leukodystrophy causative
genes with a core clinical hallmark represented by adult-onset
subacute dementia with frontal predominance revealed by T2-
weighted MRI (Supplementary Table S1). Moreover, all of these
candidate genespresentmore thanone of the following features: (1)
previously reported misdiagnosis with AD (CADASIL, HDLS, CRV,
MLD) (Guerreiro et al., 2012; Johannsen et al., 2001; Rademakers
et al., 2011; Richards et al., 2007); (2) molecular interaction with
other genes playing a key role in AD (NOTCH3 and CSF1R) (Otero
et al., 2009; Thijs et al., 2003); (3) genes taking part to APP-
amyloid beta (Ab) metabolism (NOTCH3 and HTRA1) (Grau et al.,
2005); (4) copresence of AD neuropathological hallmarks reported
(NOTCH3 and CSF1R) (Baba et al., 2006; Paquet et al., 2010); and (5)
most frequently mutated genes in adults with leukoencephalo-
pathies (NOTCH3, EIF2B4, EIF2B5, and CSF1R) (Lynch et al., 2017).
The pipeline followed in this study is described in Fig. 1.
2.2. Gene expression analysis
We have used microarray data publicly available (MouseAC
database [http://www.mouseac.org/]) (Matarin et al., 2015) and
real-time polymerase chain reaction (RT-PCR) data to analyze Arsa,
Csf1r, Eif2b1, Eif2b2, Eif2b3, Eif2b4, Eif2b5, Htra1, Notch3, and Trex1
gene expression (1) in the hippocampus and cortex of 6 different
AD mouse strains (APPPS1, HOTASTPM, HETASTPM, TPM, TAS10,
and TAU); (2) at 5 different time points (E15, 2, 4, 8, and 18months),
to comprehensively follow expression changes related to Ab plaque
density (HOTASTPM, HETASTPM, and TAS10), neurofibrillary tan-
gles (TAU) and absence of pathology (E15 and TPM). Adult APPPS1
data for hippocampus were available only for 2 months of age,
where no plaques were reported but only rare Ab oligomers in the
Fig. 1. Pipeline followed in the adult-onset leukodystrophy gene study. Abbreviations: AD, Alzheimer’s disease; BYU, Brigham Young University; MCI, mild cognitive impairment;
TK, tyrosine kinase; NIH, National Institutes of Health; UCL, University College London.
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Finally, considering that ischemic stroke is a common feature in
several leukodystrophies and frequent comorbidity in AD, we used
an in vitro model of ischemic stroke and performed OGD experi-
ments in APPPS1 primary cortical neurons to test whether leuko-
dystrophy gene expression pattern may have significantly differed
between APPPS1 and wild-type (WT) mice under stress conditions.
2.3. Genetic screening
2.3.1. The discovery cohort
The discovery cohort was composed of 332 apparently sporadic
AD cases and 676 elderly controls, neuropathologically and clinically
confirmed, originating from the United Kingdom and North America.
The mean age at disease onset was 71.66 years (range 41e94 years)
for cases and the mean age of ascertainment was 78.15 years (range
60e102 years) for controls. Most of the cases (77%) were late-onset
(>65 years at onset). Among the cases and controls, 42% and 51%
were females, respectively; 58% and 47% of the cases and controls
carried the APOE ε4 allele, respectively. The APOE ε4 allele was
significantly associated to the disease status in the National Institutes
of Health (NIH) and Alzheimer’s Disease Neuroimaging Initiative
(ADNI) series (p-value ¼ 0.02 and 1.19  10E9, respectively). This
cohort has already been described elsewhere (Sassi et al., 2016). The
threshold call rate for inclusion of the subject in analysis was 95%. On
this cohort, we performed (1) gene-based analysis (SKATand c-alpha
tests) and (2) single-variant association analysis. Finally, we followed
up, in an independent Caucasian data set, CSF1R, the only gene
significantly overexpressed during AD most severe pathology (Fig. 1,
Supplementary Table S2).
2.3.2. The follow-up data set
The follow-up data set was composed of 296 AD and 169 MCI
late-onset cases (mean age at onset >75 years) from the United
Kingdom (Supplementary Table S2). Written informed consent was
obtained for each clinically assessed individual, and the study was
approved by the appropriate institutional review boards. Allsamples had fully informed consent for retrieval and were autho-
rized for ethically approved scientific investigation (UCLH Research
Ethics Committee number 10/H0716/3, BYU IRB, Cardiff REC for
Wales 08/MRE09/38þ5, REC Reference 04/Q2404/130, National
Research Ethics Service).
2.3.3. Exome and genome sequencing
DNA was extracted from blood or brain for cases and brain only
for controls using standard protocols. Library preparation for NGS
was based on Roche Nimblegen Inc. or TruSeq, Illumina protocols
and has been described elsewhere (Sassi et al., 2016). Genome
sequencing was performed in 199 controls, from the Cache County
Study on Memory in Aging. All samples were sequenced with the
use of Illumina HiSeq technology.
Sequence alignment and variant calling were performed against
the reference human genome (UCSC hg19) and has been described
in the Supplementary materials and methods.
Initial analysis excluded pathogenic mutations in APP, PSEN1,
PSEN2, MAPT, GRN, and TREM2. All variants within the coding re-
gions of the 10 adult-onset leukodystrophy candidate genes (ARSA
[NM_000487]; CSF1R [NM_005211]; EIF2B1 [NM_001414]; EIF2B2
[NM_014239]; EIF2B3 [NM_001261418]; EIF2B4 [NM_001034116];
EIF2B5 [NM_003907]; HTRA1 [NM_002775]; NOTCH3
[NM_000435], and TREX1 [NM_016381] have been collected and
analyzed, including 20.8 Megabase pairs of coding sequence.
2.3.4. Sanger sequencing
Mutations in CSF1R TK domain and flanking regions were vali-
dated with Sanger Sequencing. CSF1Rwas screened in an additional
follow-up cohort composed of 296 AD and 169 MCI cases
(Supplementary Materials and Methods).2.4. Statistical analysis
In the single-variant analysis, allele frequencies were calculated
for each low-frequency and rare coding variant in cases and
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formed. MouseAC data have been analyzed and false discovery rate
(FDR) correction was applied.
The Supplementary data provide a more detailed description of
the methods used (mouse and human gene expression analysis,
OGD experiments, Sanger sequencing, statistical analysis, and
bioinformatics).
3. Results
3.1. Gene expression analysis
We do not report any significant differential expression in Arsa,
Csf1r, Eif2b1, Eif2b2, Eif2b3, Eif2b4, Eif2b5, Htra1, Notch3, and Trex1
until the development of severe AD pathology, markedly pro-
nounced in the most aggressive AD strain studied, HOTASTPM,
homozygous for the Swedish mutation APP p.K670N/M671L and
PSEN1 p.M146V, 8 months of age (Fig. 2AeD, Supplementary
Tables S3 and S4). Here, Csf1r was up to 2 folds significantly over-
expressed both in the hippocampus and cortex (log2FC ¼ 1.2 and
1.1; adj p-value ¼ 2.5e07 and 8.7e05, respectively) and pre-
sented a trend at 18 months both in the hippocampus and cortex
(log2FC ¼ 0.75 and 0.98; adj p-value ¼ 2.7e04 and 3e04,
respectively), in linear correlation with the most rapid and severe
dense-core plaque deposition (0.8 dense-core plaque/month and
0.5 dense-core plaque/month between 4e8 months and
8e18 months of age, respectively) (http://www.mouseac.org/)
(Fig. 2AeD, Supplementary Tables S3 and S4). Moreover, Csf1r
overexpression positively correlated also with tau pathology, sug-
gesting that Csf1r upregulation is not Ab plaque specific. By
contrast, Csf1r was downregulated when plaque deposition was
minimal (HETTASTPM, TAS10, TPM, and TAU, 2m; TAS10 and TAU,
4m) (Supplementary Tables S3 and S4). Importantly, Csf1r upre-
gulation relied on microglia infiltration and was coexpressed with
other microglia markers such as Aif1, CD68, Trem2, Tyrobp, and Grn.
Particularly, Csf1r and Grn displayed the same pattern ofFig. 2. Log2-normalized expression of Csf1r, Grn, Trem2, Tyrobp, and Aif1 in HOTASTPM mi
Trem2, Tyrobp and Aif1 in HOTASTPMmice (homozygous for the Swedish mutation APP p.K67
hippocampus (A) and cortex (B) showing coexpression of the above genes. (CeD) Progressio
HOTASTPM mice at 4 different time points (2, 4, 8, and 18 months). Significant Csf1r, Grn, Tr
months, in linear correlation with the most rapid and severe Ab plaque deposition. Abbrevia
mouseac.org/overexpression, which was between one-third to one-fourth of
Tyrobp and Trem2 overall upregulation (Fig. 3, Supplementary
Tables S3 and S4).3.2. Embryonal hippocampi and primary neuronal cortical cultures
OGD experiments
We do not report any significant differential expression in the
studied genes between APPPS1 and WT embryonal hippocampi
and APPPS1 and WT primary cortical neurons after OGD experi-
ments (Supplementary Table S5). This is likely due to the fact that
most of the leukodystrophy genes are expressed on microglia,
only moderately present in E15 hippocampi and in primary
neuronal cortical cultures. In line with this observation, Csf1r and
its ligands (Csf1 and Il34), Grn, Trem2, and Aif2 were significantly
overexpressed in both APPPS1 and WT adult hippocampi
compared to the embryonal ones (log2FC ¼ 4, 2.45, 7.9, 1.5, 2.24,
3.4 and 4.2, 2.7, 7.9, 1.77, 3.1 and 3.8, respectively) (Supplementary
Table S5). By contrast, Notch3 was up to 2 folds upregulated in
both APPPS1 and WT embryonal hippocampi compared to adult
hippocampi.
Moreover, we noticed that TREX1 50UTR displays the typical
features of many transcripts, like BACE1, that are translationally
controlled by cellular stress (O’Connor et al., 2008): TREX1 50UTR
is indeed particularly long (628 nts), GC rich (65%), and pre-
dicted to contain 6 upstream open reading frames (http://www.
ncbi.nlm.nih.gov/orffinder/) (Supplementary Fig. S2A, B), sug-
gesting TREX1 transcript might be a target of translation control
by one or more stress-activated pathway. Therefore, we have
investigated TREX1 protein levels in both APPPS1 and WT adult
brains, and we do not report any macroscopically significant
difference (Supplementary Fig. S2CI-IV). This may be due to the
fact that APPPS1 mice used for these experiments, being
2 months of age, did not display a severe pathology
(Supplementary Fig. S1).ce and related Ab plaque pathology. (AeB) Log2-normalized expression of Csf1r, Grn,
0N/M671L and PSEN1 p.M146V) at 4 different time points (2, 4, 8, and 18 months) in the
n of AD pathology in hippocampus (C) and cortex (D), based on Ab plaque density, in
em2, Tyrobp, and Aif1 overexpression (Log2FC > 1, adj. p-value < 0.05) is detected at 8
tions: Ab, amyloid beta; AD, Alzheimer’s disease. Raw data are taken from http://www.
Fig. 3. Log2FC of Csf1r, Grn, Trem2, and Tyrobp in different AD mouse strains during the most severe pathology, showing coexpression of Csf1r, Grn, Trem2, and Tyrobp. Particularly,
Csf1r and Grn display the same overexpression pattern, which is, overall, 1/3 of Trem2 and Tyrobp upregulation. Abbreviations: C, cortex; H, hippocampus. Raw data for this study are
taken from http://www.mouseac.org/
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The study population consisted of a total of 332 sporadic and
mainly LOAD cases and 676 elderly controls of British and North
American ancestry.
We do not report any pathogenic mutation in APP, PSEN1, and
PSEN2 in our cohort. However, one of the controls was a hetero-
zygous carrier of the protective variant APP p.A673T (minor allele
frequency [MAF] 7  10E4 in our cohort and MAF 5  10E4
among the European non-Finnish, ExAC database, released on
January 13, 2015).
We performed a single-variant and a single-gene association
analysis in a predefined set of adult-onset Mendelian leukodys-
trophy genes (ARSA, CSF1R, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5,
HTRA1, NOTCH3, and TREX1).
A total of 215 single-nucleotide variants have been identified.
Among these, 77 (35.8%) were nonsynonymous, 59 (27.4%) were
synonymous, and 13 (6%) UTR variants. Among the missense vari-
ants, 192 (95%) were very rare (MAF < 1%), 16 (7.9%) were low fre-
quency (1%<MAF< 5%), and 12 (5.9%)were common (MAF>5%). In
addition, we report 4 novel coding variants (NOTCH3, p.A2146E,
CSF1R p.G957R, and p.D565N and ARSA p.H425Y). Variant MAF and
novel variants were based on ExAC database, European non-Finnish
panel, and Exome Variant Server (EVS) European-American panel,
released onMarch 14, 2016, or dbSNP 137 (Supplementary Table S6).
The overall variant frequency in our cohort was in line with the
variant frequency reported in the American-European cohort in the
Exome Variant server database (Supplementary Table S7).
3.3.1. Single-geneebased analysis
We carried out gene-wide analysis to combine the joint signal
frommultiple variants (coding variants and flanking UTRs) within a
gene and to provide greater statistical power than that for single-
marker tests. All the variants (nonsynonymous, synonymous,
UTRs, and singletons) located within the studied genes and their
exon-intron flanking regions were collapsed together, and their
combined effect was studied.NOTCH3 is the only significant hit in the c-alpha test (adj
p-value¼ 0.01) (Supplementary Table S8a). The signal is driven by a
common coding synonymous variant (p.P1521P) of moderate effect
size (odds ratio ¼ 1.755, confidence interval ¼ 1.31e2.33),
significant after Bonferroni correction (adj p-value ¼ 0.02)
(Supplementary Table S9). TREX1 is another hit in the c-alpha test,
although nominally significant (adj p-value ¼ 0.56), and the signal
is mainly driven by a 50UTR and synonymous (p.Y232Y) variants
(Supplementary Tables S8a and S9). None of these variants were
predicted to affect the splicing site (http://www.umd.be/HSF/)
or a miRNA binding site (http://www.microrna.org/microrna/
home.do).
3.3.2. Single-variantebased analysis
A total of 69 rare and low-frequency coding missense mutations
were considered in the single-variantebased analysis in the studied
genes. Among these, the majority (62.8%) were singletons
(Supplementary Table S10).
Moreover, 41 missense variants (59.4%) were described as
damaging variants by at least 2 of 3 in silico prediction softwares
(SIFT, Polyphen and Mutation Taster).
The study possessed relatively low power to detect a signifi-
cant association between cases and controls for low-frequency
and rare variants, however, we analyzed these variants because
we could not preclude the possibility that high-effect risk alleles
were present.
EIF2B4 and CSF1R harbor the lowest and highest relative fre-
quency of low-frequency and rare coding variants (mean¼ 1.27 and
5.13 low-frequency-rare variants per kb of coding sequence,
respectively), with 81.25% of the rare and low-frequency coding
variability in CSF1R clustering in the Ig-like domain (Supplementary
Tables S11 and S10).
The main hits, although not significant, are rare variants with
moderate to strong effect sizes (0.6 < odds ratio < 2.73) clustering
to EIF2B4, NOTCH3, TREX1, and CSF1R (Supplementary Table S10).
None of the missense mutations leads to a premature stop
codon.
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We report 2 heterozygous missense mutations in the CSF1R TK
domain (exons 12e22, aa 582e910) in the discovery cohort
(p.L868R and p.E694K), detected in one case and one control,
respectively. Moreover, we found 4 likely pathogenic variants in the
TK domain flanking regions (aa 538e581 and 911e972): CSF1R
p.D565N, p.E916K, p.E920D, and p.G957R. We then screened CSF1R
in an independent follow-up cohort of LOAD and MCI patients, and
we identified 2 additional mutations in CSF1R TK domain (p.Q691H
and p.H703Y) (Table 1).
CSF1R TK mutation carriers (patients E, F, and H) presented a
rather homogeneous phenotype (Table 2). All these carriers were
LOAD cases displayingmemory impairment at the onset. Behavioral
and motor signs eventually appeared. In 2/3 patients, cardiovas-
cular problems and strokes preceded the dementia. The neuropa-
thology examination, available for patients H and I, showed
aggressive and diffuse neurodegeneration (Braak 6 and CERAD C).
Two of 3 carriers were heterozygous for APOE ε4 allele and do not
report any familial history for dementia. By contrast, patient H was
homozygous for APOE ε4 allele, had a family history for dementia (4
brothers) and plausibly the combination of these risk factors, likely
coupled with a pre-existent cerebrovascular disorder, may explain
the earlier age at onset compared to the other patients (64 years).
Patient I carried a missense mutation in CSF1R TK flanking region
(p.G957R) and displayed a different clinical picture, dominated by
early-onset dementia (49 years) and language problems at the
onset. Despite the small sample size, we do not report any associ-
ation between age at onset, severity of the disease progression, and
disease duration.
Detailed clinical description was available for 4 patients. The
clinical, neuroimaging, and neuropathological features of the car-
riers are summarized in Table 2.
3.3.4. Patient H (p.L868R)
This male patient deceased at the age of 75 years. He was one of
5 siblings who all survived to old age, of whom 4 experienced
memory problems or received a diagnosis of dementia or AD. The
informant reported he experienced sudden decline following a
stroke at 65 years. He had obvious short-term memory problems
and dysphasia. At this stage, he was considered to have probable
vascular dementia. Pathological examination of the brain concluded
this patient had a high probability of AD. Neurofibrillary tangle
stage was consistent with Braak stage VI, while plaque pathology
met CERAD criteria for score C. In addition, there was evidence of
amyloid angiopathy, focal TDP-43 positivity, and occasional glial
inclusions.
3.3.5. Patient E (p.Q691H)
This patient deceased at the age of 89 years. She complained of
memory problems at the age of 82 years, and 2 years later under-
went anMRI scan, which showed symmetric patchy periventricular
hyperintensities, mainly pronounced in the frontal lobe (Fig. 4A).
Following annual visits involving neuropsychiatric testing, she
received a diagnosis of AD at the age of 86 years. In the 3 years
following her diagnosis, her symptoms were quite stable. She
experienced a rapid deterioration in the last 7e8months before her
death.
3.3.6. Patient F (p.H703Y)
This patient had a strong history of cardiovascular disease and
reported memory symptoms, at the age of 79 years, followed by
irritability and anxiety and 2 years later received a clinical diagnosis
of probable AD. Computed tomography of the brain showed
supratentorial atrophy, temporal lobe atrophy, and slight vascular
changes. The patient also experienced intermittent motor
Table 2
CSF1R TK and TK flanking region mutation carrier description
Patient CSF1R
mutation
APOE AO-AD Family
history of
dementia
Disease
duration
First
symptom
Behavioral
symptom
Motor symptom Vascular risk
factors
Misdiagnosis CT/MRI Neuropath
Patient D p.D565N 34 92 NA NA NA NA NA NA NA NA
Patient E p.Q691H 34 82e89 Negative 7y, rapid
deterioration
during the
last 7 months
Memory problems No Symmetric patchy
periventricular
hyperintensities,
mainly pronounced
in the frontal lobes
Patient F p.H703Y 34 79e82 Negative 3y Memory problems Irritability and
anxiety
Intermittent mild
rigidity,
tremor and
bradykinesia,
mild left hemiparesis
Bilateral severe carotid
artery stenosis,
vertebrobasilar TIA
Vascular
dementia
Hippocampal and
temporal lobe
atrophies, subcortical
microbleeds
(right basal ganglia),
and small
ischemic stroke (left
pons), lacunar
infarct right parietal
lobe, centrum
semiovale bilateral
lesions
Patient H p.L868R 44 64e75 4/4 siblings
diagnosed
with
dementia
11y Short-term memory
problems and
dysphasia
Stroke at 65y Vascular
dementia
Severe microbleeding Extensive Ab and tau
deposition (Braak VI
and CERAD C), amyloid
angiopathy
and focal TDP-43
Patient I p.G957R NA 49e57 Negative 8y Language problem Aggression and
paranoia later
in the course
of the disease
No PNFA Braak VI and CERAD C
Key: Ab, amyloid beta; AO-AD, age at onset-age at death; symp., symptoms; CT/MRI, computed tomography/magnetic resonance imaging; NA, not available; TIA, transient ischemic attack; PNFA, progressive nonfluent aphasia.
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Fig. 4. MRI scans, Sanger sequencing validation, and mutation domain conservation for patients E, F, and H. (AeB) Coronal T2-weighted MRI scan of patients E and F (for both taken
2y after onset of symptoms, aged 84y and 81y, respectively) showing symmetric patchy periventricular hyperintensities, mainly pronounced in the frontal lobes (A) and bilateral
lesions localized to the centrum semiovale (B) (arrows). (CeE) Genomic DNA Sanger sequencing validation of CSF1R c.2073G>C, c.2107C>T, and c.2603 T>G mutations. (FeH) cDNA
Sanger sequencing validation of c.2073G>C, c.2107C>T, and c.2603 T>Gmutations. For patients F and H, cDNA sequence highlights a possible allelic imbalance, supporting the likely
functional effect of gDNA c.2107C>T and gDNA c.2603 T>Gmutations. (IeK) Conservation of p.Q691H, p. H703Y, and p.L868R in different species. PhastCons and PhyloP scores range
between 0e1 and 14 to þ6, respectively. For PhastCons, the closer to one, the more conserved; for PhyloP, conserved sites are assigned positive scores. Abbreviation: MRI,
magnetic resonance imaging.
C. Sassi et al. / Neurobiology of Aging 66 (2018) 179.e17e179.e29179.e24symptoms that included mild rigidity, tremor, and slowness of
movement. The MRI scans showed central and cortical atrophies
and mild to moderate medial temporal lobe atrophy, as well as a
small old hemorrhage, ischemic lesions, and bilateral lesions
localized to the centrum semiovale (Fig. 4B).
Patient I’s detailed description is in the Supplementary data.3.4. Tissue expression of CSF1R
We followed up our findings checking CSF1R expression in LOAD
and control brain samples. We selected the entorhinal cortex (EC)
and BA9 preassociation cortex (BA9) because the brain regions
primarily affected by AD spreading pathology (Khan et al., 2014).
CSF1R was overexpressed in AD EC compared to AD BA9 preasso-
ciation cortex and control brains (Fig. 5A).
It was not possible to quantitatively compare levels of CSF1R in
all the 3 CSF1R TK mutation carriers due to a lack of available brain
tissue. However, cDNA Sanger Sequencing revealed a possible allelic
imbalance, with the WT allele normally expressed and the mutated
one only moderately both for patient F (p.H703Y) and patient H
(p.L868R), suggesting a functional role of these mutations
(Fig. 4GeH). RNA from the EC and the BA9 preassociation cortex
was available for patient H and showed significantly lower
expression of CSF1R (1) in the EC compared to BA9 preassociationcortex and (2) in patient H’s EC compared to other AD patients and
controls for all CSF1R primers tested (Fig. 5AeB).4. Discussion
Mendelian adult-onset leukodystrophies clinically resemble
common dementias such as AD, potentially implying they may be
influenced by shared genetic risk factors.
To comprehensively investigate this hypothesis, we applied a
combination of gene expression analysis in different AD mouse
strains at diverse developmental stages (http://mouseac.org/) and
single-variantebased and single-geneebased genetic screening in a
cohort composed of 332 LOAD cases and 676 elderly controls from
the United Kingdom and United States (Fig. 1). Divergent gene
expression between AD andWTmouse strains was only detected in
aged mice with severe dense-core plaque deposition (Fig. 2AeD,
Supplementary Tables S3 and S4).
Csf1r was the only gene displaying a significant differential
expression between AD and WT mouse strains. It was up to 2 folds
significantly overexpressed both in the hippocampus and cortex in
HOTASTPMmice aged 8months (log2FC¼ 1.2 and 1.1; adj p-value¼
2.5E07 and 8.7E05, respectively), and its overexpression linearly
correlated with the rapidity of dense-core plaque deposition rather
than with their overall load (Fig. 2AeD, Supplementary Tables S3
and S4). By contrast, Csf1r was downregulated when the
Fig. 5. Tissue expression of CSF1R. (A) Relative CSF1R and GAPDH expression assessed by RT-PCR in postmortem brain RNA from normal control and AD individuals. (B)
Expression of CSF1R transcripts and the house-keeping gene GAPDH in the EC and BA9 preassociation cortex (BA9) from patient H (c.2603T>G, p.L868R). RT-PCR for CSF1R exon
11 to 20, exon 11 to 19, exon 17 to 20, and exon 17 to 22 as indicated. Abbreviations: EC, entorhinal cortex; BA, Brodmann area; AD, Alzheimer’s disease; C, normal control;
RT-PCR, Real Time PCR.
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S4), suggesting that Csf1r upregulation was tightly driven by and
consequential to dense-core plaque formation and, to a lesser
extent, neurofibrillary tau tangles.
Importantly, Csf1r expression pattern relied on microglia infil-
tration as overexpression of Aif1 suggested (Fig. 2AeB,
Supplementary Tables S3 and S4). Csf1r was coexpressed and
shared the same expression pattern with Trem2, Tyrobp, and Grn,
critical genes expressed on microglia, whose loss of function mu-
tation in homozygosity is causative for adult-onset leukodystro-
phies such as polycystic lipomembranous osteodysplasia with
sclerosing leukoencephalopathy (PLOSL) (TREM2 and TYROBP)
(Paloneva et al., 1993), and in heterozygosity causes frontotemporal
lobar degeneration with TDP-43 inclusions (FTLD-TDP43) (GRN)
(Baker et al., 2006) or is a significant risk factor for sporadic AD
(TREM2) (Guerreiro et al., 2013), and whose overexpression is
protective and limits AD neuropathology through a very effective
clearance of Ab plaques (GRN and TREM2) (Minami et al., 2014).
Notably, in all the strains, Csf1r and Grn degree of expression
correlated, and this was generally one-third of Tyrobp and Trem2
overall upregulation (Fig. 3, Supplementary Tables S3 and S4). This
effect was not simply due to the aging process: we do not report
significant differential expression in Csf1r, Grn, Trem2, and Tyrobp in
the cortex and hippocampus of WT mice between 2 and 18 months
of age (0.04 < log2FC < 0.2 and 0.04 < log2FC < 0.4 in the hip-
pocampus and cortex, respectively) (Supplementary Tables S3 and
S4). Importantly, CSF1R, TREM2, and TYROBP have been already
shown to cointeract (Otero et al., 2009) (https://string-db.org/).
Here, we report GRN as an additional potential key player and its
coexpression on microglia strengthens its synergic function.
Therefore, this may imply that CSF1R, in concert with TREM2,
TYROBP, and GRN, plays a key role in Ab plaque removal, hypothesis
supported by previous literature, reporting CSF1R overexpressed in
AD patients particularly around senile plaques and taking part in Ab
removal (Akiyama et al., 1994) (Murphy et al., 2000) (Mizuno et al.,
2011) (Boissonneault et al., 2009).
By contrast, no differential expression of any adult-onset leu-
kodystrophy gene was observed in the E15 hippocampi and pri-
mary cortical neurons after OGD experiments between APPPS1 andWT strains, likely given the fact that these genes, although
expressed in neurons, mainly exert a critical role on microglia
(TREX1 and CSF1R), astrocytes (NOTCH3 and HTRA1), and endothe-
lial cells (NOTCH3, HTRA1, TREX1, EIF2B2, EIF2B3, and EIF2B5) (http://
web.stanford.edu/group/barres_lab/brain_rnaseq.html) that are
minimally present in E15 hippocampi and primary cortical
neuronal cultures.
In our discovery and validation cohorts, we detected 3 rare
coding variants in the TK domain of CSF1R in 3 LOAD cases, one of
these neuropathologically confirmed. Moreover, we report 2 cases
harboring rare mutations in the TK flanking regions (aa 538e580
and aa 911e972, encoded by exon 12 and 22, respectively), where
an additional causative mutation for HDLS has been recently
described (c.1736G>A, p.R579Q) (Ghadiri et al., 2014). These vari-
ants are very likely pathogenic: they cluster to highly conserved
domains among different species (average PhyloP and PhastCons
scores ¼ 2.2 and 0.6, respectively) (Fig. 4IeK) and have been
detected only in cases.
Moreover, CSF1R p.L868R is a functional mutation as it was
associated with a reduced expression of the mutated allele (Fig. 4H)
and decreased CSF1R expression in the EC, a region primarily
affected in AD and generally displaying CSF1R upregulation in AD
patients (Fig. 5A and B). Importantly, a different amino acid change,
clustering within the same codon (p.L868P) has been reported as de
novo mutation, causative for HDLS (Rademakers et al., 2011).
Remarkably, to date, any missense mutation in Mendelian gene
domains harboring heterozygous causative mutations for auto-
somal dominant disorders such as familial AD and FTD (APP, PSEN1,
PSEN2, and MAPT) has always been reported as pathogenic
(Supplementary Table S12, http://www.molgen.ua.ac.be/
ADMutations/). The only exception is represented by APP p.A673T,
which is a very rare protective factor for AD (Jonsson et al., 2012). In
addition, an intronic single-nucleotide polymorphism (SNP) in
CSF1R, rs1010101, displayed a trend toward association (adj p-
value ¼ 2E4), in a genome-wide association study performed in
Caucasian LOAD patients (Wijsman et al., 2011), supporting CSF1R
possible role in LOAD progression.
CSF1R mutation carriers presented a homogeneous phenotype,
closely resembling HDLS. First, the symptom at onset was a
C. Sassi et al. / Neurobiology of Aging 66 (2018) 179.e17e179.e29179.e26memory deterioration followed by behavioral changes in 3/3 car-
riers. Second, T2-weighted MRI, available for 2 patients, showed
symmetric patchy periventricular hyperintensities, mainly pro-
nounced in the frontal lobe (patient E) and bilateral lesions local-
ized to the centrum semiovale (patient F) (Fig. 4B), that represent
common MRI findings in HDLS patients (Ghadiri et al., 2014),
(Rademakers et al., 2011) (Boissé et al., 2010) (Mateen et al., 2010).
Finally, senile plaques, amyloid angiopathy, and tau tangles have
been reported also in the cortex and hippocampus of 2 familial and
1 sporadic HDLS patients (Baba et al., 2006) (Browne et al., 2003).
Importantly, these 3 HDLS patients displaying AD neuropatholog-
ical hallmarks presented an overall early age at onset (average
54 years [range 78e32 years]), developed Parkinsonism, atypical
Parkinsonism, and motor impairment with increasing rigidity
(Supplementary Table S13). By contrast, only patient F (20%) dis-
played intermittent mild rigidity, tremor, and bradykinesia, arguing
for Parkinsonism, however within a neurological picture already
dominated by cerebrovascular disorders, and patient H reported no
sign of motor impairment besides 2 falls in few months. Never-
theless, although an earlier age at onset, Parkinsonism and
distinctive motor features may be more common in HDLS patients
presenting AD neuropathology than AD cases carrying CSF1R TK
mutations; the average disease duration for both these HDLS and
AD patients was 7 years. Therefore, in the absence of accurate dif-
ferential diagnostic criteria, this combination of clinical, neuro-
imaging, and neuropathological features strikingly overlapping
makes the definitive neurological diagnosis a real conundrum. The
fact that potentially pathogenic mutations in the TK domain in
heterozygosity may be detected either in databases and apparently
healthy controls, may give rise to HDLS or may be rare risk factors
for AD may be due to different factors modifying the mutation
penetrance (Karle et al., 2013). Analogously to GRN missense mu-
tations in AD and FTD, CSF1R mutation penetrance may be influ-
enced by APOE genotype, aging, disease duration, or comorbidities
such as cerebrovascular accidents, for which CSF1R has been
already shown to play a critical protective role (Luo et al., 2013). In
addition, it may be plausible that most HDLS patients may not
display AD neuropathology due to the rapid progression of the
disease (Baba et al., 2006).
Finally, NOTCH3 was a significant hit in the gene-based analysis
(c-alpha test, adj p-value ¼ 0.01). The signal was driven both by a
common synonymous variant (p.P1521P) (Supplementary Table S9)
that may influence gene expression (Sauna and Kimchi-Sarfaty,
2011) and 3 rare coding variants with large effect size (p.V1952M,
p.V1183M, p.H170R, 2.73 <0R < 1.63), whose carrier frequency was
between 2 and 3 times higher in cases compared to controls,
although not significant (Supplementary Tables S6 and S10).
Importantly, these rare variants (p.V1952M, p.V1183M, and
p.H170R) have been already reported to be significantly associated
with severity of white matter lesions in elderly with hypertension
(Schmidt et al., 2011), suggesting a potential role as diseasemodifier
in LOAD. In addition, we report a heterozygous pathogenic gain of
cysteine mutation in NOTCH3 (p.R578C) detected in 1 control and
already reported in a Korean patient with clinical suspicious
CADASIL, implying that the penetrance of NOTCH3 mutations is
variable (Kim et al., 2014).
Therefore, although canonical NOTCH3 mutations causative for
CADASIL are highly stereotyped: (1) cluster in epidermal growth
factorelike repeat domains, (2) in exons 3 and 4, and (3) consist in
the gain or loss of cysteine; nevertheless, our study reports a
possible synergetic effect of common and rare variants in NOTCH3
potentially influencing AD susceptibility through an increased risk
for small vessel disease or white matter lesions. Our hypotheses are
supported by a growing body of evidence showing that (1) NOTCH3
common variants (rs1043994, rs10404382, rs10423702, andrs1043997) are significantly associated with white matter lesions in
elderly with hypertension (Schmidt et al., 2011) and (2) rare non-
cysteine mutations may be pathogenic as they have been reported
in Korean and Japanese CADASIL patients, in a French case with
small vessel disease, and have been associated to severe white
matter lesions in elderly patients (Fouillade et al., 2008; Mizuno
et al., 2008; Schmidt et al., 2011). Importantly, our findings add
evidence to the pathogenic link between AD and CADASIL, dis-
playing clinical shared features and rarely, as only few cases have
been reported, neuropathological hallmarks characterized by Ab
plaques, amyloid angiopathy, and neurofibrillary tangles (Guerreiro
et al., 2012; Gray et al., 1994; Paquet et al., 2010; Thijs et al., 2003).
Biologically, presenilins cleaving both APP and NOTCH3 may bridge
the gap between AD and CADASIL. However, whether NOTCH3
mutations or differential expression may accelerate a pre-existing
AD or AD may contribute to CADASIL exacerbation remains to be
elucidated.
In summary, adult-onset Mendelian leukodystrophy genes are
not common factors in AD, therefore the genetic screening plays a
pivotal role in the differential diagnosis. However, genetically
diagnosed HDLS and CADASIL patients may display clinical, neu-
roimaging, and neuropathological features meeting the diagnostic
criteria for AD, leaving the definitive diagnosis a significant chal-
lenge. Here, we report neuropathologically confirmed AD patients
carrying likely pathogenic mutations in CSF1R TK domain and a
potential association between AD and NOTCH3. Our study provides
compelling evidence that HDLS, CADASIL, and AD may represent
shades of the same disease spectrum. Moreover, we support pre-
vious studies, suggesting that CSF1R, in concert with TREM2,
TYROBP, and GRN, may play a critical role in Ab plaque clearance and
therefore may represent a pivotal, although rare, genetic factor
influencing AD susceptibility. Given the very rare frequency of
CSF1R TK pathogenic mutations detected in the screened patients
(0.3% LOAD carriers), our hypotheses should foster genetic
screening in larger cohorts of both early-onset AD and LOAD cases
and functional studies.
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Supplementary Fig. S1. (A) Histological cortical section of APPPS1 mouse, 2 months of age, stained with Ab oligomers (Ab126892). Rare Ab oligomers are detected around small
cortical vessels (B) and in the extracellular space, likely phagocytated by astrocytes (C), showing a very mild pathology and disease state. No Ab plaques have been detected (data not
shown).
Supplementary Fig. S2. (A) 50UTR length of the studied adult-onset leukodystrophy genes. TREX1 presents the longest 50UTR region (628nts). (B) TREX1 displays analogous
50UTR features of BACE1, known to be subjected to translational control: (1) 50UTR length (628 and 453 nts, respectively); (2) GC content (65% and 77%, respectively), and (3)
predicted open reading frames (ORFs) (6 and 3, respectively). (CIeIV) Cortical histological sections of APPPS1 and WT mice (aged 2 months), stained with TREX1 antibody
(Abnova 68191), which mainly binds to endothelial cells and to a lesser extent neurons. No macroscopical difference has been detected between APPPS1 and WT mice.
Abbreviation: WT, wild type.
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